REDmedic

REDmedic is a South Korean biotechnology company specializing in the development of treatments for rare and endocrine diseases. Established in 2021, the company focuses on high-unmet-need pediatric genetic disorders, utilizing protein engineering to create next-generation biologics. Its primary pipeline includes candidates for achondroplasia and hypophosphatasia, targeting specific genetic pathways to restore normal physiological function. REDmedic operates with strategic backing from Handok, a prominent Korean pharmaceutical firm, to advance its clinical development programs. The company is committed to becoming a global leader in the rare disease space through innovative R&D and precision therapeutics.